KAHN SCOTT D 4

What Happened Scott Kahn, a director of Exagen Inc. (XGN), was granted a derivative award on 2026-06-09 covering 37,500 shares. The grant is reported at $0.00 (no cash paid at grant); the filing classifies this as an award/option rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-06-09; reported grant amount: 37,500 shares; reported price: $0.00.
• Instrument: derivative award (option) — the filing indicates these are options, not an immediate stock purchase or sale.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Vesting (Footnote F1): the full award becomes vested and exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next annual meeting of stockholders, subject to Mr. Kahn’s continued board service through the vesting date.
• Filing timeliness: the Form 4 was filed 2026-06-22 (13 days after the transaction), which appears late versus the usual 2-business-day reporting requirement.

Context This was a director compensation award (stock option grant) rather than a purchase or sale. Such grants are common for board service and do not indicate an immediate liquidity event — the options must vest per the schedule before exercisable. The $0 reported here reflects no cash changing hands at grant; the actual exercise price and tax implications (if any) would be disclosed elsewhere or in a more detailed plan document.